The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.

JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.

Felmetatug vedotin’s exit could be bad news for Mersana.

The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.